NASDAQ · ABSI
Absci Corporation
Healthcare · Biotechnology
$9.54▲ 3.87% ($0.35)today
As of 12:11 PM ET
Market cap
$1.64B
P/E
N/M
EPS (TTM)
-$0.77
Next earnings
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 0.0%
- Discount rate
- 14.6%
USD · TTM ending Jun 30, 2026 · Price used $9.54 · Price Oct 26, 4:11 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 112.11% over the last year. Revenue declined 62.28% over the trailing twelve months. Operating margin moved from -2,846.57% to -8,411.27%. Free cash flow declined 42.03% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -8,411.27%. A decisive move in revenue — currently down 62.28% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
11
Buy
1
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 12, 2026
Q3 FY26 · EPS est -$0.19 · Revenue est $664.2K
Q2 FY26
Reported Aug 11, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$0.18
Estimate
-$0.19
Year over year
n/m
Vs prior quarter
n/m
2 beats · 2 misses in the last 4 quarters
Institutional Sentiment
Absci Corporation · ABSI
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.